Merck expands presence in hematology with Terns Pharma acquisition

Traders Union
All News
Companies
Merck acquires Terns Pharma

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Market Voices

Companies

Ashutosh Sureka

25.03.2026

Merck expands presence in hematology with Terns Pharma acquisition — Merck acquires Terns Pharma

Merck has announced an agreement to acquire Terns Pharma, a move aimed at expanding its portfolio in the hematology field.

The deal will add a potential best-in-class treatment candidate for certain patients with chronic myeloid leukemia to Merck's pipeline. The acquisition underscores Merck's commitment to advancing innovative therapies in oncology and its strategy to strengthen its presence in blood cancer treatments.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Merck has recently advanced research on new therapies, sharing Phase 3 trial results for an investigational HIV treatment at CROI2026. The company will also present new long-term HPV data at EUROGIN 2026. These developments reflect Merck’s continuing focus on new treatment options across its pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Bitcoin price prediction based on MVRV: Indicator points to BTC undervaluation

By Mikhail Vnuchkov
8 hours ago

Bitcoin price prediction based on MVRV: Indicator points to BTC undervaluation

Editors' Picks

Amazon flooded with AI books: Crisis of trust in literature market

By Eugene Komchuk
Yesterday

Amazon flooded with AI books: Crisis of trust in literature market

Editors' Picks

From stablecoins to the metaverse: Meta's biggest bets that failed

By Pavlo Kot
27.06.2026

From stablecoins to the metaverse: Meta's biggest bets that failed

Editors' Picks

All Editors' Top Picks

Latest Merck News

Merck stock jumps 2.31% as company expands HIV treatment access through ADAPs

By Ciaran Ryan
Yesterday

Merck stock jumps 2.31% as company expands HIV treatment access through ADAPs

Companies

Merck stock slides amid strong selling pressure despite Phase 3 immunology trial update

By Jose Antonio Gastelum
22.06.2026

Merck stock slides amid strong selling pressure despite Phase 3 immunology trial update

Companies

Merck stock drops 1.25% as company posts strong Phase 3 HIV data with Gilead Sciences

By Ezequiel Gomes
09.06.2026

Merck stock drops 1.25% as company posts strong Phase 3 HIV data with Gilead Sciences

Companies

Mikhail Vnuchkov
8 hours ago

Bitcoin price prediction based on MVRV: Indicator points to BTC undervaluation

Eugene Komchuk
Yesterday

Amazon flooded with AI books: Crisis of trust in literature market

Pavlo Kot
27.06.2026

From stablecoins to the metaverse: Meta's biggest bets that failed

Johnathan Maverick
26.06.2026

Gold and silver: Why to buy in July

Anastasiia Chabaniuk
26.06.2026

AI push hits Apple: MacBook and iPad prices rise as shares fall

Hanna Syniavska
17 min ago

GEOD issuance rate set to halve tomorrow, Kyle Samani notes

Artem Shendetskii
27 min ago

Joanna Stern: Traditional business banking remains inefficient and inconvenient

Elena Nikulina
37 min ago

Suze Orman: Building emergency savings can earn $100 bonus at Alliant Credit Union

Jose Antonio Gastelum
52 min ago

Bitcoin could move toward $57,300, Joao Wedson predicts

Anastasiia Chabaniuk
52 min ago

Kevin Warsh may be the real deal for the Federal Reserve, Gordon Johnson notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Eugene Komchuk
2 hours ago

Solana Company to help Kazakhstan build blockchain megacity

Solana Company to help Kazakhstan build blockchain megacity

Hanna Syniavska
4 hours ago

Mag 7 loses $2.3 trillion as investors shift into chip stocks

Mag 7 loses $2.3 trillion as investors shift into chip stocks

Olga Shendetskaya
6 hours ago

ECB rate path remains uncertain despite U.S.-Iran ceasefire

ECB rate path remains uncertain despite U.S.-Iran ceasefire

Andrey Mastykin
8 hours ago

Brent and WTI decline as Gulf ceasefire hopes pressure crude

Brent and WTI decline as Gulf ceasefire hopes pressure crude

Igor Krasulya
9 hours ago

Yen hits historic low as U.S. rate gap keeps pressure on Japan

Yen hits historic low as U.S. rate gap keeps pressure on Japan

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Alphabet rebounds as AI demand offsets capex risk

Anton Kharitonov
Now

Microsoft steadies as AI capex re-rating pressures shares

Anton Kharitonov
Now

Apple seeks recovery after sharp drop

Mykhailo Ihnatenko
Now

Intel nears ATH despite sector-wide profit-taking

Mykhailo Ihnatenko
Now

Silver heads for its worst month since 2011

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.